<h1>Legal risks for book launch on obesity and GLP-1 drugs: disclaimers, promotion rules, IP, and regulatory compliance</h1> A literary event hosted by an NGO and publisher publicized a new book on obesity and weight management authored by a medical specialist and a co-author; attendees included government and cultural figures and a journalist-moderator. The book discusses clinical topics including GLP-1 medications, efficacy, side effects, and policy-relevant India-specific health concerns, and emphasizes lifestyle measures alongside medical interventions. Legal considerations include potential regulatory scrutiny of medical claims and drug information, the need for clear medical disclaimers and avoidance of individualized medical advice, intellectual property and promotional compliance for pharmaceutical references, and reliance limits noted in the press-release attribution to a third-party news agency.